GoAI
Get started
Tandem Diabetes Care, Inc. logo

Tandem Diabetes Care, Inc.

TNDM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$22.32

−$0.25 · -1.11%

Aug 21, 4:00 PM ET

TNDM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

30

Weakening

Sentiment

70

Bullish

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
John F. Sheridan
Listed since
Nov 14, 2013
Employees
2,500

Market position

Day range

Current $22.32

52-week range

Current $22.32

Open
$22.79
Previous close
$22.57
Volume
1.64M
0.71× average
Average volume
2.3M
Average daily volume
Market cap
1.53B USD
Beta
1.54
Market reference 1
50-day average
$18.0229
+23.84% above average
200-day average
$19.5517
+14.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.83B USD
P/E (TTM)
-24.03×
P/B (TTM)
11.71×
P/S (TTM)
1.47×
EV / EBITDA
-10.49×
Earnings yield
-13.84%
Free cash flow yield
-2.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.01%
Operating margin
-4.13%
Net margin
-6.08%
Return on equity
-131.93%
Return on assets
-23.23%
Return on invested capital
-11.88%

Financial health

Debt / equity
5.67×
Current ratio
2.55×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%28%-6%-40%Gross margin, FY2021: 53.53%Gross margin, FY2022: 51.54%Gross margin, FY2023: 49.17%Gross margin, FY2024: 52.07%Gross margin, FY2025: 52.31%Operating margin, FY2021: 3.22%Operating margin, FY2022: -11.59%Operating margin, FY2023: -31.19%Operating margin, FY2024: -10.54%Operating margin, FY2025: -7.70%Net margin, FY2021: 2.21%Net margin, FY2022: -11.81%Net margin, FY2023: -29.77%Net margin, FY2024: -10.21%Net margin, FY2025: -20.17%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.53%. Gross margin FY2022 51.54%. Gross margin FY2023 49.17%. Gross margin FY2024 52.07%. Gross margin FY2025 52.31%. Operating margin FY2021 3.22%. Operating margin FY2022 -11.59%. Operating margin FY2023 -31.19%. Operating margin FY2024 -10.54%. Operating margin FY2025 -7.70%. Net margin FY2021 2.21%. Net margin FY2022 -11.81%. Net margin FY2023 -29.77%. Net margin FY2024 -10.21%. Net margin FY2025 -20.17%.

Income trends

Revenue

1.01B USD+7.93%

Operating income

−78.12M USD+21.19%

Net income

−204.71M USD-113.18%
Income trends across reported periods1.14B USD640.35M USD141.16M USD−358.03M USDRevenue, FY2021: 702.8M USDRevenue, FY2022: 801.22M USDRevenue, FY2023: 747.72M USDRevenue, FY2024: 940.2M USDRevenue, FY2025: 1.01B USDOperating income, FY2021: 22.65M USDOperating income, FY2022: −92.85M USDOperating income, FY2023: −233.23M USDOperating income, FY2024: −99.13M USDOperating income, FY2025: −78.12M USDNet income, FY2021: 15.57M USDNet income, FY2022: −94.59M USDNet income, FY2023: −222.61M USDNet income, FY2024: −96.03M USDNet income, FY2025: −204.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 702.8M USD. Revenue FY2022 801.22M USD. Revenue FY2023 747.72M USD. Revenue FY2024 940.2M USD. Revenue FY2025 1.01B USD. Operating income FY2021 22.65M USD. Operating income FY2022 −92.85M USD. Operating income FY2023 −233.23M USD. Operating income FY2024 −99.13M USD. Operating income FY2025 −78.12M USD. Net income FY2021 15.57M USD. Net income FY2022 −94.59M USD. Net income FY2023 −222.61M USD. Net income FY2024 −96.03M USD. Net income FY2025 −204.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.01B USD940.2M USD747.72M USD801.22M USD702.8M USD
Cost of goods sold483.89M USD450.63M USD380.03M USD388.23M USD326.58M USD
Gross profit530.85M USD489.57M USD367.69M USD412.99M USD376.22M USD
Research and development174.84M USD198.88M USD248.42M USD170.15M USD92.05M USD
Selling, general, and administrative434.13M USD389.82M USD352.5M USD335.68M USD261.51M USD
Operating expenses608.97M USD588.7M USD600.92M USD505.83M USD353.56M USD
Interest income9.09M USD17.99M USD22.86M USD6.06M USD674K USD
Interest expense7.91M USD7.42M USD9.88M USD6.21M USD6.04M USD
Depreciation and amortization17.67M USD158K USD15.72M USD14.33M USD13.85M USD
Operating income−78.12M USD−99.13M USD−233.23M USD−92.85M USD22.65M USD
Net income−204.71M USD−96.03M USD−222.61M USD−94.59M USD15.57M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+20.32%
11 comparable reports
Latest EPS result
-0.31
Estimate -0.32 · Beat by 3.35%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.06-0.2-0.46-0.72Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MetQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 0.01, estimate -0.23, surprise +104.35%, Beat. Q2 2025, reported Apr 30, 2025: actual -0.67, estimate -0.6, surprise -11.67%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.48, estimate -0.4, surprise -20.00%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.31, estimate -0.31, surprise 0.00%, Met estimate. Q1 2026, reported Feb 19, 2026: actual -0.01, estimate -0.05, surprise +80.00%, Beat. Q2 2026, reported May 7, 2026: actual -0.3, estimate -0.46, surprise +34.78%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.31, estimate -0.321, surprise +3.35%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates302M270.9M239.8M208.71MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 252.45M USD, estimate 250.58M USD, surprise +0.75%, Beat. Q2 2025, reported Apr 30, 2025: actual 234.42M USD, estimate 220.32M USD, surprise +6.40%, Beat. Q3 2025, reported Aug 6, 2025: actual 240.68M USD, estimate 238.58M USD, surprise +0.88%, Beat. Q4 2025, reported Nov 6, 2025: actual 249.25M USD, estimate 235.76M USD, surprise +5.72%, Beat. Q1 2026, reported Feb 19, 2026: actual 290.38M USD, estimate 277.01M USD, surprise +4.83%, Beat. Q2 2026, reported May 7, 2026: actual 247.22M USD, estimate 240.41M USD, surprise +2.83%, Beat. Q3 2026, reported Aug 6, 2026: actual 254.56M USD, estimate 254.99M USD, surprise -0.17%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 266.06M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$30.17

35.17% upside
Past 12 months12-month forecastHigh $55.00Average $30.17Low $15.50

Rating distribution

39 ratings
Strong buy00%
Buy2462%
Hold1538%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
Deutsche BankdowngradeBuyHold

TNDM news

benzinga.com

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the…

Read source
marketbeat.com

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi

Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product…

Read source
zacks.com

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.

Read source
marketbeat.com

Tandem Diabetes Care Q2 Earnings Call Highlights

Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to…

Read source
seekingalpha.com

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.48 per share a year ago.

Read source

TNDM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TNDM

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
92.61M
Weight
0.08%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
42.64M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
40.42M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
30.65M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
17.91M
Weight
0.04%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
16.16M
Weight
0.25%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
15.4M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
14.55M
Weight
0.10%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research TNDM

research.disclaimer